Corstrata Announces Rafael Mazuz as New Senior Advisor

USA - English

• USA - English

SAVANNAH, Ga., Oct. 29, 2019 /PRNewswire-PRWeb/ -- Corstrata, Inc., a leading, tech-enabled, virtual wound management company, has announced the appointment of Rafael Mazuz as a Senior Advisor to the company. Mazuz is the Managing Director of Diligence Wound Care Global, the world's leading wound care and regenerative medicine advisory firm, empowering executives, investors, and specialists to be confident in their wound care business decisions.

As a former corporate wound center executive, Mazuz brings deep industry knowledge combined with powerful wound care intelligence and a global network of experts. He advises the majority of top global wound care product brands and investors, serves on the boards of innovative wound-related startups, speaks at key industry events such as The European Wound Management Association (EWMA) conference and The Symposium on Advanced Wound Care (SAWC) and serves on the editorial advisory board of Today's Wound Clinic.

"The overwhelming majority of advanced wound care innovation and investment focus in recent decades has been on the physical products used in treatment," said Mazuz. "However, the opportunity to empower clinicians to better treat and manage patients with complex wounds is likely far greater, despite the relative lack of focus historically."

"Having actively followed and been in contact with Corstrata since its inception, I'm thrilled to be collaborating with them to further activate and share their expertise with the massive cohort of clinicians who are otherwise faced with difficult-to-heal wounds without the benefit of years of specialized training, experience, and advanced technologies."

"We are honored for Mr. Mazuz to join Corstrata as a Senior Advisor," said Katherine Piette, Chief Executive Officer and Founder of Corstrata. "We believe his vast knowledge of the national and international wound industry, coupled with his expertise in healthcare strategy, business development, and venture capital will be invaluable during Corstrata's next phase of growth."

Corstrata is tackling the big challenge of chronic wound care. This "silent epidemic" affects more than 6.5M people in the U.S. at a staggering cost of $39B annually. These numbers are on the rise due to the increased incidence of obesity, diabetes, vascular disease, and other contributing diseases. This problem is compounded by the scarcity and lack of access to wound experts, especially in the post-acute provider space where only 10% of certified wound care nurses practice. This results in a tremendous rate of misdiagnosis, ineffective treatments, poor clinical outcomes, and wasted resources, all producing critical data amassed by Corstrata in its analytics platform to inform its treatment algorithms for driving optimal care. Corstrata's service-enabled technology platform provides access to wound experts to improve clinical outcomes at a lower cost per wound patient.

SOURCE Corstrata